Moberg Pharma AB interim report January - September 2017
SUCCESS FOR NEW SKINNINE-MONTH PERIOD (JAN-SEPT 2017) · Net revenue SEK 348.9 million (244.9) · EBITDA SEK 62.4 million (65.9) · EBITDA excluding capital gains* SEK 49.4 million (24.7) · EBITDA for current product portfolio SEK 75.2 million(76.0) · Operating profit (EBIT) SEK 33.5 million (55.1) · Net profit after tax SEK 1.6 million (35.1) · Diluted earnings per share SEK 0.09 (2.45) · Operating cash flow per share SEK 1.40 (-1.64) THIRD QUARTER (JUL-SEPT 2017) · Net revenue SEK 108.3 million (104.1) · EBITDA SEK 36.0 million (29.0) · EBITDA